 Stephen Frankel
Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Fibrosis | 8 | 2011 | 321 | 1.260 |
Why?
| | Lung Diseases | 5 | 2012 | 690 | 0.780 |
Why?
| | Idiopathic Pulmonary Fibrosis | 6 | 2015 | 500 | 0.700 |
Why?
| | Vasculitis | 2 | 2012 | 65 | 0.640 |
Why?
| | Hospital Mortality | 2 | 2014 | 773 | 0.640 |
Why?
| | Critical Illness | 3 | 2017 | 640 | 0.620 |
Why?
| | Lung Diseases, Interstitial | 9 | 2015 | 495 | 0.570 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2012 | 20 | 0.450 |
Why?
| | Hospitals, Veterans | 1 | 2012 | 244 | 0.370 |
Why?
| | Wounds and Injuries | 2 | 2017 | 674 | 0.360 |
Why?
| | Cause of Death | 1 | 2012 | 362 | 0.350 |
Why?
| | Arteritis | 1 | 2010 | 27 | 0.350 |
Why?
| | Fibroblasts | 5 | 2011 | 834 | 0.350 |
Why?
| | Churg-Strauss Syndrome | 4 | 2018 | 17 | 0.340 |
Why?
| | Respiration, Artificial | 2 | 2017 | 528 | 0.340 |
Why?
| | Intensive Care Units | 1 | 2014 | 614 | 0.330 |
Why?
| | Eosinophilia | 1 | 2011 | 186 | 0.330 |
Why?
| | Respiratory Tract Diseases | 1 | 2010 | 139 | 0.320 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 127 | 0.300 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2008 | 83 | 0.290 |
Why?
| | Colitis, Ischemic | 1 | 2007 | 6 | 0.290 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2007 | 25 | 0.280 |
Why?
| | Escherichia coli O157 | 1 | 2007 | 30 | 0.280 |
Why?
| | Escherichia coli Infections | 1 | 2007 | 102 | 0.270 |
Why?
| | Venous Thromboembolism | 1 | 2009 | 230 | 0.260 |
Why?
| | Exercise Therapy | 1 | 2009 | 351 | 0.250 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2004 | 286 | 0.250 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2005 | 140 | 0.240 |
Why?
| | Connective Tissue Diseases | 3 | 2013 | 71 | 0.240 |
Why?
| | Granulomatosis with Polyangiitis | 3 | 2018 | 41 | 0.240 |
Why?
| | Apoptosis | 4 | 2011 | 2349 | 0.230 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2005 | 1128 | 0.220 |
Why?
| | Antiviral Agents | 2 | 2021 | 642 | 0.220 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2022 | 92 | 0.220 |
Why?
| | Lung | 6 | 2014 | 3521 | 0.220 |
Why?
| | Precancerous Conditions | 1 | 2004 | 155 | 0.210 |
Why?
| | Adenoma | 1 | 2004 | 187 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 660 | 0.200 |
Why?
| | Smoking | 1 | 2009 | 1382 | 0.200 |
Why?
| | Humans | 33 | 2022 | 114045 | 0.200 |
Why?
| | Hypertension, Pulmonary | 2 | 2009 | 1736 | 0.190 |
Why?
| | Biomarkers | 1 | 2010 | 3397 | 0.170 |
Why?
| | Mycophenolic Acid | 2 | 2013 | 76 | 0.170 |
Why?
| | Diagnosis, Differential | 4 | 2011 | 1331 | 0.160 |
Why?
| | fas Receptor | 2 | 2011 | 91 | 0.150 |
Why?
| | Aged | 13 | 2017 | 18969 | 0.140 |
Why?
| | Ganciclovir | 1 | 2017 | 48 | 0.140 |
Why?
| | Middle Aged | 14 | 2018 | 26605 | 0.140 |
Why?
| | Interferon-gamma | 2 | 2013 | 719 | 0.140 |
Why?
| | Mutation | 3 | 2022 | 3338 | 0.130 |
Why?
| | Cytomegalovirus | 1 | 2017 | 143 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 5 | 2015 | 2272 | 0.130 |
Why?
| | Male | 17 | 2017 | 55396 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2017 | 180 | 0.120 |
Why?
| | Survival Rate | 4 | 2015 | 1638 | 0.120 |
Why?
| | Female | 16 | 2018 | 59324 | 0.110 |
Why?
| | Interleukin-6 | 1 | 2017 | 673 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 82 | 0.110 |
Why?
| | Immunosuppressive Agents | 2 | 2018 | 641 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2016 | 265 | 0.110 |
Why?
| | Lung Neoplasms | 1 | 2004 | 2159 | 0.100 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2011 | 9 | 0.100 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2011 | 9 | 0.100 |
Why?
| | Sepsis | 1 | 2017 | 507 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2013 | 217 | 0.100 |
Why?
| | Respiratory Insufficiency | 2 | 2017 | 286 | 0.100 |
Why?
| | Pulmonary Alveoli | 2 | 2011 | 372 | 0.100 |
Why?
| | Pulmonary Eosinophilia | 1 | 2011 | 25 | 0.100 |
Why?
| | Rheumatic Diseases | 1 | 2011 | 49 | 0.090 |
Why?
| | Bronchoscopy | 1 | 2011 | 196 | 0.090 |
Why?
| | Biopsy | 2 | 2014 | 1024 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2017 | 4392 | 0.090 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 222 | 0.080 |
Why?
| | Antibodies, Antinuclear | 1 | 2009 | 58 | 0.080 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2009 | 20 | 0.080 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2009 | 28 | 0.080 |
Why?
| | Idiopathic Interstitial Pneumonias | 1 | 2009 | 46 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2013 | 328 | 0.080 |
Why?
| | Disease Progression | 2 | 2015 | 2371 | 0.080 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2015 | 60 | 0.080 |
Why?
| | Up-Regulation | 1 | 2011 | 802 | 0.070 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 319 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2008 | 281 | 0.070 |
Why?
| | Prognosis | 3 | 2009 | 3315 | 0.070 |
Why?
| | Arthritis, Rheumatoid | 1 | 2015 | 1002 | 0.070 |
Why?
| | Survival Analysis | 1 | 2010 | 1206 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2010 | 268 | 0.070 |
Why?
| | Comorbidity | 1 | 2011 | 1447 | 0.070 |
Why?
| | Cells, Cultured | 4 | 2011 | 3861 | 0.070 |
Why?
| | Pericardium | 1 | 2007 | 50 | 0.070 |
Why?
| | Anastomosis, Surgical | 1 | 2007 | 135 | 0.070 |
Why?
| | Biopsy, Needle | 1 | 2007 | 180 | 0.070 |
Why?
| | Cysts | 1 | 2007 | 92 | 0.070 |
Why?
| | Colectomy | 1 | 2007 | 86 | 0.070 |
Why?
| | Rare Diseases | 1 | 2007 | 88 | 0.070 |
Why?
| | Scleroderma, Systemic | 1 | 2007 | 90 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2008 | 244 | 0.070 |
Why?
| | Autoantibodies | 1 | 2013 | 1347 | 0.070 |
Why?
| | Abdominal Pain | 1 | 2007 | 134 | 0.060 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2005 | 8 | 0.060 |
Why?
| | Wound Healing | 1 | 2008 | 254 | 0.060 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2006 | 33 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 907 | 0.060 |
Why?
| | Respiratory Function Tests | 3 | 2014 | 522 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2010 | 12521 | 0.060 |
Why?
| | Protein Binding | 2 | 2021 | 1888 | 0.060 |
Why?
| | Heart Rate | 1 | 2009 | 710 | 0.060 |
Why?
| | Walking | 1 | 2009 | 422 | 0.060 |
Why?
| | Colonoscopy | 1 | 2007 | 197 | 0.060 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 73 | 0.060 |
Why?
| | Pleura | 1 | 2004 | 18 | 0.060 |
Why?
| | Proline | 1 | 2005 | 72 | 0.060 |
Why?
| | Vital Capacity | 2 | 2015 | 254 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 164 | 0.060 |
Why?
| | Hyperplasia | 1 | 2004 | 163 | 0.060 |
Why?
| | Echocardiography | 1 | 2007 | 569 | 0.060 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2004 | 110 | 0.060 |
Why?
| | Gene Expression | 2 | 2009 | 1417 | 0.060 |
Why?
| | Cohort Studies | 2 | 2015 | 4883 | 0.060 |
Why?
| | Interleukin-4 | 1 | 2004 | 204 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 296 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2017 | 9049 | 0.050 |
Why?
| | Bleomycin | 1 | 2004 | 228 | 0.050 |
Why?
| | Incidence | 1 | 2009 | 2314 | 0.050 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1624 | 0.050 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 367 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2007 | 2537 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2015 | 813 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 532 | 0.050 |
Why?
| | Fibrosis | 1 | 2004 | 452 | 0.050 |
Why?
| | Age Factors | 1 | 2009 | 2885 | 0.050 |
Why?
| | Longitudinal Studies | 3 | 2014 | 2384 | 0.050 |
Why?
| | Radiography | 1 | 2004 | 803 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 124 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2010 | 6306 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2022 | 112 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2015 | 1422 | 0.050 |
Why?
| | Antigen-Antibody Reactions | 1 | 2021 | 49 | 0.050 |
Why?
| | Macrophages, Alveolar | 1 | 2004 | 348 | 0.050 |
Why?
| | Surface Plasmon Resonance | 1 | 2021 | 81 | 0.050 |
Why?
| | Receptors, Virus | 1 | 2021 | 75 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 556 | 0.040 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 471 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 101 | 0.040 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 129 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2015 | 1078 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2004 | 1947 | 0.040 |
Why?
| | Pneumonia | 1 | 2004 | 563 | 0.040 |
Why?
| | Amino Acids | 1 | 2022 | 445 | 0.040 |
Why?
| | Cell Line | 3 | 2011 | 2629 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 295 | 0.040 |
Why?
| | Mice | 4 | 2011 | 14843 | 0.040 |
Why?
| | Kinetics | 1 | 2021 | 1547 | 0.040 |
Why?
| | Binding Sites | 1 | 2021 | 1166 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 69 | 0.040 |
Why?
| | Virus Activation | 1 | 2017 | 78 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 8614 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 445 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2550 | 0.030 |
Why?
| | Adult | 4 | 2017 | 30375 | 0.030 |
Why?
| | Mice, Inbred C3H | 2 | 2005 | 242 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2009 | 1791 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2017 | 1656 | 0.030 |
Why?
| | Rituximab | 1 | 2013 | 148 | 0.030 |
Why?
| | Length of Stay | 1 | 2017 | 957 | 0.030 |
Why?
| | Animals | 4 | 2011 | 31565 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2013 | 66 | 0.030 |
Why?
| | Microscopic Polyangiitis | 1 | 2012 | 12 | 0.030 |
Why?
| | Necrosis | 1 | 2012 | 209 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 57 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 133 | 0.020 |
Why?
| | Alanine-tRNA Ligase | 1 | 2009 | 4 | 0.020 |
Why?
| | Threonine-tRNA Ligase | 1 | 2009 | 4 | 0.020 |
Why?
| | Elastin | 1 | 2009 | 78 | 0.020 |
Why?
| | Oximetry | 1 | 2009 | 79 | 0.020 |
Why?
| | Myoblasts | 1 | 2009 | 76 | 0.020 |
Why?
| | Syndrome | 1 | 2009 | 330 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 492 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2007 | 64 | 0.020 |
Why?
| | Transfection | 1 | 2009 | 863 | 0.020 |
Why?
| | Collagen | 1 | 2009 | 414 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 547 | 0.020 |
Why?
| | Medical Records | 1 | 2006 | 153 | 0.020 |
Why?
| | Consensus Sequence | 1 | 2005 | 70 | 0.020 |
Why?
| | NF-kappa B | 1 | 2009 | 636 | 0.020 |
Why?
| | Asparagine | 1 | 2005 | 29 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2011 | 2562 | 0.020 |
Why?
| | COS Cells | 1 | 2005 | 175 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1518 | 0.010 |
Why?
| | Sequence Deletion | 1 | 2005 | 166 | 0.010 |
Why?
| | Serine | 1 | 2005 | 125 | 0.010 |
Why?
| | Cytoplasm | 1 | 2005 | 255 | 0.010 |
Why?
| | Growth Substances | 1 | 2004 | 138 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 103 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2005 | 345 | 0.010 |
Why?
| | Logistic Models | 1 | 2009 | 1829 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 145 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2009 | 946 | 0.010 |
Why?
| | Th2 Cells | 1 | 2004 | 154 | 0.010 |
Why?
| | Cell Communication | 1 | 2004 | 277 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 796 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 397 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2009 | 3003 | 0.010 |
Why?
| | Inflammation | 1 | 2012 | 2464 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 2173 | 0.010 |
Why?
| | Cell Membrane | 1 | 2005 | 670 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1014 | 0.010 |
Why?
| | Phosphorylation | 1 | 2005 | 1558 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 607 | 0.010 |
Why?
| | Prospective Studies | 1 | 2011 | 6195 | 0.010 |
Why?
| | Young Adult | 1 | 2009 | 10444 | 0.010 |
Why?
| | Adolescent | 1 | 2009 | 17800 | 0.010 |
Why?
|
|
Frankel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|